FDA CLEARS INVESTIGATIONAL NEW DRUG APPLICATION FOR MESOBLAST TO USE REMESTEMCEL-L IN PATIENTS WITH ACUTE RESPIRATORY DISTRESS SYNDROME CAUSED BY COVID-19 - Seite 3

Release authorized by the Chief Executive.

For further information, please contact:

Julie Meldrum                                                    
Corporate Communications                                
T: [phone]                                           
E: [e-mail]                       

Schond Greenway
Investor Relations 
T: [phone]
E: [e-mail]